Trastuzumab monotherapy followed by the combination of trastuzumab and letrozole in post-menopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to a nonsteroidal aromatase inhibitor

Projekt

Trastuzumab monotherapy followed by the combination of trastuzumab and letrozole in post-menopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to a nonsteroidal aromatase inhibitor

Automatisch geschlossen · 2005 bis 2011

Baumann Michael, Köberle Dieter

Art

Klinische Forschung

Reichweite

Multizentrisch, KSSG als teilnehmendes Zentrum

Bereiche

Medizinische Onkologie und Hämatologie

Status

Automatisch geschlossen

Start

2005

Ende

2011

Studiendesign

multicenter two-step phase II trial

Schlagwörter (Tags)

combination of trastuzumab and letrozole, post-menopausal women, ER-positive, HER-2 positive

Projektpartner

Dr. med. Dieter Köberle Kantonsspital St. Gallen

Kurzbeschreibung/Zielsetzung

The primary objective is to determine the efficacy of combined letrozole (L) and trastuzumab (T) in postmenopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to sequential monotherapy of a nonsteroidal aromatase inhibitor followed by
trastuzumab.
The secondary objectives are to evaluate the safety profile of this combination by recording the adverse drug reactions and abnormal laboratory values during treatment and to investigate predictive markers for response to treatment with letrozole and trastuzumab in
HER-2 positive, ER-positive positive tumors.